Last $10.68 USD
Change Today -0.09 / -0.84%
Volume 264.6K
As of 10:28 AM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

infinity pharmaceuticals inc (INFI) Snapshot

Open
$10.69
Previous Close
$10.77
Day High
$10.85
Day Low
$10.55
52 Week High
09/10/13 - $21.60
52 Week Low
05/7/14 - $8.40
Market Cap
518.9M
Average Volume 10 Days
750.3K
EPS TTM
$-3.04
Shares Outstanding
48.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INFINITY PHARMACEUTICALS INC (INFI)

infinity pharmaceuticals inc (INFI) Related Businessweek News

No Related Businessweek News Found

infinity pharmaceuticals inc (INFI) Details

Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to people with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies and inflammatory diseases. The company is conducting DUOTM, a randomized, monotherapy Phase 3 study of IPI-145 in patients with relapsed/refractory chronic lymphocytic leukemia; an ongoing Phase 1 dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies; a Phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of IPI-145 in patients with rheumatoid arthritis; and a Phase 2a trial of IPI-145 in patients with mild allergic asthma, as well as completed a Phase 1 trial of IPI-145 in healthy adult subjects. It also develops IPI-443, an oral inhibitor of PI3K-delta and gamma; and IPI-940, an inhibitor of fatty acid amide hydrolase. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

infinity pharmaceuticals inc (INFI) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $552.0K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $378.8K
President of Research & Development
Total Annual Compensation: $465.8K
Chief Scientific Officer
Total Annual Compensation: $366.4K
Compensation as of Fiscal Year 2013.

infinity pharmaceuticals inc (INFI) Key Developments

Infinity Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Infinity Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, loss from operations was $35,222,000 against $32,755,000 a year ago. Net loss was $38,024,000 $0.78 per basic and diluted share against $32,591,000 $0.68 per basic and diluted share a year ago. For the six months, loss from operations was $76,517,000 against $60,416,000 a year ago. Net loss was $80,290,000 $1.66 per basic and diluted share against $59,917,000 $1.25 per basic and diluted share a year ago.

Infinity Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 05, 2014

Infinity Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 05, 2014

Infinity Pharmaceuticals, Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-18-2014 09:30 AM

Infinity Pharmaceuticals, Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-18-2014 09:30 AM. Venue: InterContinental Hotel Boston, 510 Atlantic Avenu, Boston, MA 02210, United States. Speakers: Adelene Q. Perkins, Chairman of the Board, Chief Executive Officer and President, Jaren Madden, Director, IR & Corporate Communications, Lawrence E. Bloch, Chief Financial Officer, Chief Business Officer, Principal Accounting Officer, Executive Vice President, Treasurer and Secretary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INFI:US $10.68 USD -0.09

INFI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INFI.
View Industry Companies
 

Industry Analysis

INFI

Industry Average

Valuation INFI Industry Range
No financial data is available for INFI.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INFINITY PHARMACEUTICALS INC, please visit www.infi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.